Our data are consistent with a model in which dysregulation of C-HGF expression in GBM results in activation of c-MET signaling promoting downstream signaling driving growth, motility and invasiveness in GBM in a paracrine/autocrine fashion. The gene discussed is MET; the disease is glioblastoma.